Pure Global
NCT05309213

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Leukemia
Drug/Device/Intervention
IM19 CAR-T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 01, 2022
End date
Jun 01, 2025
Enrollment
58 participants
Primary outcome

Incidence of Treatment Related adverse events (AEs),Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow)

Summary

This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19
 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia

ICD-10 classifications
Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05309213
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05309213 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 58 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.